Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Research & Development (2016 - 2025)

Heron Therapeutics' Research & Development history spans 14 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 17.87% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $12.4 million, down 25.5%, while the annual FY2025 figure was $12.4 million, 25.5% down from the prior year.
  • Research & Development reached $3.7 million in Q4 2025 per HRTX's latest filing, up from $3.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $42.1 million in Q1 2022 to a low of -$13.7 million in Q4 2022.
  • Average Research & Development over 5 years is $14.1 million, with a median of $8.3 million recorded in 2023.
  • Peak YoY movement for Research & Development: tumbled 147.6% in 2022, then skyrocketed 156.76% in 2023.
  • A 5-year view of Research & Development shows it stood at $28.9 million in 2021, then crashed by 147.6% to -$13.7 million in 2022, then skyrocketed by 156.76% to $7.8 million in 2023, then crashed by 59.27% to $3.2 million in 2024, then rose by 17.87% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Research & Development are $3.7 million (Q4 2025), $3.5 million (Q3 2025), and $2.9 million (Q2 2025).